Nama's AI scorecard currently rates Veeva Systems Buy (8.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is VEEV's P/E ratio?

Veeva Systems trades at a trailing price-to-earnings ratio of 35.0.

When does VEEV report earnings?

Veeva Systems's next scheduled report is on Nov 25, 2026. Analysts expect EPS of $2.34.

What is the VEEV price target?

The median analyst price target from 27 analysts is $305.00, with a range of $180.00 – $375.00.

Is VEEV Shariah compliant?

Nama's AAOIFI-style screen reads Veeva Systems as Can't Tell. A figure the screen needs is missing, so it can't tell.

Nama Insights

Veeva Systems (VEEV)

Healthcare · Health Information Services · NYSE

S&P 500

Veeva Systems (VEEV) is a Healthcare company in the Health Information Services industry. It has a market capitalization of $49.18B, a trailing price-to-earnings ratio of 35.0 and a free-cash-flow yield of 2.8%. Over the most recent reported fiscal year, revenue grew 16.3% and free cash flow per share grew 28.5%. Nama's AI scorecard rates it Buy, 8.5 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Buy · 8.5/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Lagging · -3.0% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Can't Tell

A figure the screen needs is missing, so it can't tell.

Off its high

-6.8%

How far the last close sits under the highest price of the past five years.

Market cap	$49.18B
Trailing P/E	35.0
Price / book	6.6
Price / sales	14.2
FCF yield	2.8%
Dividend yield	—
Gross margin	75.0%
Operating margin	29.9%
Net margin	29.3%
Revenue growth (YoY)	+16.3%
Revenue growth (3-yr annual)	+14.0%
EPS growth (YoY)	+21.9%
FCF/share growth (YoY)	+28.5%
Beta	0.9
Exchange	NYSE
Sector	Healthcare
Industry	Health Information Services

VEEV earnings

Next report: Nov 25, 2026 (Q3 2027, EPS estimate $2.34). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2027	Aug 26, 2026	$2.35	$2.22	+5.9%	$927.96M
Q1 2027	Jun 3, 2026	$2.24	$2.14	+4.7%	$882.95M
Q4 2026	Mar 4, 2026	$2.06	$1.94	+6.2%	$835.95M
Q3 2026	Nov 20, 2025	$2.04	$1.95	+4.6%	$811.24M

VEEV analyst price target

Median target $305.00 from 27 analysts, ranging $180.00 – $375.00.

Health Information Services peers

Ticker	Company	Market cap	P/E
TEM	Tempus AI	$13.87B	—
BTSG	BrightSpring Health Services	$13.36B	39.3
HNGE	Hinge Health	$9.34B	51.7
HQY	HealthEquity	$8.57B	23.3
TXG	10x Genomics	$7.72B	296.4
DOCS	Doximity	$5.79B	23.7
WAY	Waystar	$5.45B	17.2
HTFL	Heartflow	$4.56B	—

Explore live VEEV data on Nama Insights →

Recent Congressional trades

Veeva Systems trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Rob Bresnahan	House	Buy	$1,001 - $15,000	Jun 23, 2025
Rob Bresnahan	House	Sell	$1,001 - $15,000	Jun 9, 2025
Byron Donalds	House	Sell	$1,001 - $15,000	Apr 14, 2025
Byron Donalds	House	Sell	$1,001 - $15,000	Apr 14, 2025
John James	House	Sell	$1,001 - $15,000	Sep 2, 2024
John James	House	Buy	$1,001 - $15,000	Sep 2, 2024

VEEV FAQ

Is VEEV a buy?: Nama's AI scorecard currently rates Veeva Systems Buy (8.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is VEEV's P/E ratio?: Veeva Systems trades at a trailing price-to-earnings ratio of 35.0.
When does VEEV report earnings?: Veeva Systems's next scheduled report is on Nov 25, 2026. Analysts expect EPS of $2.34.
What is the VEEV price target?: The median analyst price target from 27 analysts is $305.00, with a range of $180.00 – $375.00.
Is VEEV Shariah compliant?: Nama's AAOIFI-style screen reads Veeva Systems as Can't Tell. A figure the screen needs is missing, so it can't tell.